{"query":"Epirium Bio Russell Cox mitochondrial therapeutics news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://epirium.com/","title":"Epirium Bio","content":"Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel","score":0.99995804,"raw_content":null},{"url":"https://epirium.com/wp-content/uploads/2024/12/Epirium-Bio-Announces-FDA-Clearance-of-IND-Application-for-MF-300-and-Appointment-of-Alex-Casdin-as-New-CEO-and-Russell-Cox-as-Executive-Chairman.pdf","title":"[PDF] Epirium Bio Announces FDA Clearance of Investigational New Drug","content":"Epirium Bio Announces FDA Clearance of Investigational New Drug Application for MF-300 and Appointment of Alex Casdin as New Chief Executive Officer and Russell Cox as Executive Chairman MF-300 Phase 1 Patient Screening Commencing Expected First Patient Dosed in Q1 2025 San Diego, December 23, 2024. The U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MF-300, a first-in-class orally administered, 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor in development for the treatment of sarcopenia, or age-induced muscle weakness. About Epirium Bio Epirium, a biopharmaceutical company based in San Diego, California, has identified and established an IP-protected platform of orally bioavailable small molecules that constitute a new class of therapeutics with the potential to improve function in neuromuscular diseases, including sarcopenia and spinal muscular atrophy.","score":0.9997408,"raw_content":null},{"url":"https://www.businesswire.com/news/home/20200414005322/en/Epirium-Bio-Receives-FDA-Orphan-Drug-Designation-for-EB-002--Epicatechin-for-the-Treatment-of-Duchenne-and-Becker-Muscular-Dystrophy","title":"Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 ((+)","content":"“We are delighted that the data presented on EB 002 supported the FDA's grant of an orphan-drug designation,” said Russell Cox, Epirium's chief","score":0.99963164,"raw_content":null},{"url":"https://www.swfinstitute.org/news/76857/vertex-ventures-places-hope-in-epirium-bio","title":"Vertex Ventures Places Hope in Epirium Bio | SWFI","content":"Epirium Bio is headed up by Russell Cox as CEO. Cox is the former CEO of Vital Therapies, Inc. and COO of Jazz Pharmaceuticals. In January","score":0.9995234,"raw_content":null},{"url":"https://epirium.com/press-releases/","title":"Press Releases - Epirium Bio","content":"Epirium Bio Announces First Participants Dosed in Phase I Clinical Trial Evaluating MF-300 for the Treatment of Sarcopenia","score":0.99940693,"raw_content":null}],"response_time":0.83,"request_id":"2b482af3-5548-4547-89fb-d0db220795e3"}